Pharmaceutical & Biotechnology

The Pharmaceutical and Biotechnology segment pours considerable resources into research and development initiatives. The EPA estimates that 21% of segment sales are reinvested in R&D each year. In addition to these financial resources, segment companies invest substantial amounts of time. Time and money are two of this segment’s most critical considerations.

According to the Congressional Office of Technology, Pharmaceutical companies spend nearly $600 million to develop a single new drug and shepherd it through the government’s approval process. To develop a new medicinal agent, R&D labs evaluate as many as 10,000 compounds and, once a lead compound is both identified and characterized, another 1,000 similar substances will be synthesized and studied by laboratory assay systems. And the time needed to complete this analysis – over 15 years.

Control Station speeds the testing and analysis of discrete compounds and synthesized substances by quickly determining appropriate process settings. Our solutions provide a high degree of accuracy and consistency throughout testing and analysis as well as improved safety and regulatory compliance related to the handling of hazardous compounds. With rapid and accurate simulation capabilities, Control Station gives two critical resources back – time and money.

» View Key Clients